The short version of clinical endpoint fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
During the 1982–83 event, jack mackerel and anchoveta populations were reduced, scallops increased in warmer water, but hake followed cooler water down the continental slope, while shrimp and sardines moved southward, so some catches decreased while others increased. Horse mackerel have increased in the region during warm events. Shifting locations and types of fish due to changing conditions create challenges for the fishing industry. Peruvian sardines have moved during El Niño events to Chilean areas. Other conditions provide further complications, such as the government of Chile in 1991 creating restrictions on the fishing areas for self-employed fishermen and industrial fleets. Southern Brazil and northern Argentina also experience wetter than normal conditions during El Niño years, but mainly during the spring and early summer. Central Chile receives a mild winter with large rainfall, and the Peruvian-Bolivian Altiplano receives more precipitation during its rainy season, sometimes being exposed to unusual winter snowfall events. Drier and hotter weather occurs in parts of the Amazon River Basin, Colombia, and Central America. During a time of La Niña, drought affects the coastal regions of Peru and Chile. From December to February, northern Brazil is wetter than normal. La Niña causes higher than normal rainfall in the central Andes, which in turn causes catastrophic flooding on the Llanos de Mojos of Beni Department, Bolivia. Such flooding is documented from 1853, 1865, 1872, 1873, 1886, 1895, 1896, 1907, 1921, 1928, 1929 and 1931.
Argon–argon (Ar–Ar) Iodine–xenon (I–Xe) Lanthanum–barium (La–Ba) Lead–lead (Pb–Pb) Lutetium–hafnium (Lu–Hf) Hafnium–tungsten dating (Hf-W) Potassium–calcium (K–Ca) Rhenium–osmium (Re–Os) Uranium–uranium (U–U) Krypton–krypton (Kr–Kr) Beryllium (10Be–9Be)
== Interactions == LRP5 has been shown to interact with AXIN1. Canonical WNT signals are transduced through Frizzled receptor and LRP5/LRP6 coreceptor to downregulate GSK3beta (GSK3B) activity not depending on Ser-9 phosphorylation. Reduction of canonical Wnt signals upon depletion of LRP5 and LRP6 results in p120-catenin degradation.
== Biology and genetics == S. boulardii was originally described as a species distinct from S. cerevisiae based on phenotypic traits, including the inability to ferment galactose, a reported lack of sporulation under standard laboratory conditions, and increased tolerance to human body temperature, gastric acidity, and digestive enzymes compared with many S. cerevisiae strains. Subsequent molecular and genomic analyses, however, have shown that S. boulardii falls within the genetic diversity of S. cerevisiae, forming a distinct clade most closely related to wine-associated strains. Like other S. cerevisiae strains, S. boulardii possesses 16 nuclear chromosomes and a 2-micron plasmid, and is diploid, carrying genetic determinants for both mating types (MATa and MATα). However, the MATa locus in S. boulardii contains mutations predicted to impair mating and sporulation, which may account for its reduced or absent sporulation phenotype under laboratory conditions. S. boulardii shares with other S. cerevisiae strains the production of secreted proteins reported to interfere with certain bacterial pathogens and their toxins, including a 63-kDa phosphatase (Pho8) that reduces Escherichia coli endotoxin activity and a 54-kDa serine protease (Ysp3) capable of degrading Clostridioides difficile toxins A and B. An additional, as-yet-unidentified protein of approximately 120 kDa has been reported to inhibit cholera toxin–induced increases in intracellular cyclic AMP (cAMP).
Vitamin E deficiency due to either malabsorption or metabolic anomaly can cause nerve problems due to poor conduction of electrical impulses along nerves due to changes in nerve membrane structure and function. In addition to ataxia, vitamin E deficiency can cause peripheral neuropathy, myopathies, retinopathy, and impairment of immune responses.
Sources: en.wikipedia.org
A lower-end product includes salt, hydrogenated fat, monosodium glutamate, flavor enhancers, and flavors. It is labelled as "beef flavor" without beef. A mid-end product typically combines cheaper sources of flavor with actual meat/bone/vegetable (usually first cooked into an extract) and/or animal fat. For example, Maggi bouillon cubes are manufactured from iodized salt, hydrogenated palm oil, wheat flour, flavor enhancers (monosodium glutamate, disodium inosinate, disodium guanylate), chicken fat, chicken meat, sugar, caramel, yeast extract, onion, spices (turmeric, white pepper, coriander), and parsley. A high-end product typically mainly rely on meat/bone/vegetable (usually extracted) for the meaty flavor and savoriness, such as described in a 2004 patent. As an example, "Better than Bouillion" is made from roasted chicken, salt, sugar, maltodextrin, chicken stock, yeast extract, onion powder, garlic powder, tumeric, and flavoring.
== Developments == Due to the shortage of plutonium-238, a new kind of RTG assisted by subcritical reactions has been proposed. In this kind of RTG, the alpha decay from the radioisotope is also used in alpha-neutron reactions with a suitable element such as beryllium. This way a long-lived neutron source is produced. Because the system has a criticality close to but less than 1, i.e. Keff < 1, a subcritical multiplication is achieved which increases the neutron background and produces energy from fission reactions. Though the number of fissions produced in the RTG is very small (making their gamma radiation negligible), because each fission releases over 30 times more energy than each alpha decay (200 MeV compared to 6 MeV), up to a 10% energy gain is attainable, which translates into a reduction of the 238Pu needed per mission. The idea was proposed to NASA in 2012 for the yearly NASA NSPIRE competition, which translated to Idaho National Laboratory at the Center for Space Nuclear Research (CSNR) in 2013 for studies of feasibility. However the essentials are unmodified. RTG have been proposed for use on realistic interstellar precursor missions and interstellar probes.An example of this is the Innovative Interstellar Explorer (2003–current) proposal from NASA.An RTG using 241Am was proposed for this type of mission in 2002.This could support mission extensions up to 1000 years on the interstellar probe, because 241Am decays more slowly than 238Pu.Other isotopes for RTG were also examined in the study, looking at traits such as watt/gram, half-life, and decay products.
== Evolution == Corticotrophin releasing hormone (CRH) evolved ~500 million years ago in an organism that subsequently gave rise to both chordates and arthropods. The binding site for this was single CRH like receptor. In vertebrates this gene was duplicated leading to the extant CRH1 and CRH2 forms. Additionally four paralogous ligands developed including CRH, urotensin-1/urocortin, urocortin II and urocortin III.
=== Towards separation === After Slovenia and Croatia declared independence from the Socialist Federal Republic of Yugoslavia in 1991, Bosnia and Herzegovina declared its sovereignty in October 1991 and organized a referendum on independence in March 1992. The decision of the Parliament of the Socialist Republic of Bosnia and Herzegovina on holding the referendum was taken after the majority of Bosnian Serb members had left the assembly in protest. These Bosnian Serb assembly members invited the Bosnian Serb population to boycott the referendum held on 29 February and 1 March 1992. The turnout in the referendum was 64-67% and the vote was 98% in favor of independence. Independence was declared on 5 March 1992 by the parliament. The referendum and the murder of two Bosnian Serb members of a wedding procession in Sarajevo the day prior to the referendum was utilized by the Bosnian Serb political leadership as a reason to start road blockades in protest. Further political and social deterioration followed, leading to the Bosnian War. The Socialist Republic of Bosnia and Herzegovina was renamed the Republic of Bosnia and Herzegovina on 8 April 1992, losing the adjective "Socialist". It began moving toward a fully capitalist economic system. The republic retained socialist realist symbols pending the end of the Yugoslav Wars. The republic was led by Alija Izetbegović in a fractious political environment. In 1992, the Republic declared independence from the Socialist Federal Republic of Yugoslavia.
Drugs continue to be taken off the market due to late discovery of hepatotoxicity. Due to its unique metabolism and close relationship with the gastrointestinal tract, the liver is susceptible to injury from drugs and other substances. 75% of blood coming to the liver arrives directly from gastrointestinal organs and the spleen via portal veins that bring drugs and xenobiotics in near-undiluted form. Several mechanisms are responsible for either inducing hepatic injury or worsening the damage process. Many chemicals damage mitochondria, an intracellular organelle that produces energy. Its dysfunction releases excessive amount of oxidants that, in turn, injure hepatic cells. Activation of some enzymes in the cytochrome P-450 system such as CYP2E1 also lead to oxidative stress. Injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside the liver. This promotes further liver damage. Non-parenchymal cells such as Kupffer cells, collagen-producing stellate cells, and leukocytes (i.e. neutrophil and monocyte) also have a role in the mechanism.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.